Design of a tumorigenicity test for induced pluripotent stem cell (iPSC)-derived cell products

Journal of Clinical Medicine

Volumn 4, Issue 1, 2015, Pages 159-171

  Kawamata, Shin ^a,b   Kanemura, Hoshimi ^a,b   Sakai, Noriko ^b   Takahashi, Masayo ^b   Go, Masahiro J ^a  

^a FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^b RIKEN Center for Biosystems Dynamics Research   (Japan)

Author keywords

IPSC; PSC derived cell therapy; RPE; Tumorigenicity test

Indexed keywords

ARTICLE; CARCINOGEN TESTING; CARCINOGENICITY; CELL PROLIFERATION; CELL THERAPY; CELL TRACKING; CELL TRANSPLANTATION; CHROMOSOMAL INSTABILITY; CLINICAL PROTOCOL; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MODEL; DOSE CALCULATION; EXOME; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENDER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; KARYOTYPING; MICROENVIRONMENT; MYCOPLASMA; NONHUMAN; PHENOTYPE; PIGMENT EPITHELIUM; PLURIPOTENT STEM CELL; PRACTICE GUIDELINE; STUDY DESIGN;

EID: 85067220119     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm4010159     Document Type: Article

References (20)

1. Strauss, S. Geron trial resumes, but standards for stem cell trials remain elusive. Nat. Biotechnol. 2010, 28, 989–990
2. Schwartz, S.D.; Hubschman, J.P.; Heilwell, G.; Franco-Cardenas, V.; Pan, C.K. Embryonic stem cell trials for macular degeneration: A preliminary report. Lancet 2012, 379, 713−720
3. Cyranoski, D. Stem cells cruise to clinic. Nature 2013, 494, doi:10.1038/494413a.
4. Reardon, S.; Cyranoski, D. Japan stem-cell trial stirs envy. Nature 2014, 513, 287–288
5. Researchers Perform World’s 1st iPS Cell Implant Surgery on Human. Available online: http://ajw.asahi.com/article/sci_tech/medical/AJ201409130015 (accessed on 13 September 2014).
6. Frey-Vasconcells, J.; Whittlesey, K.J.; Baum, E.; Feigal, E.G. Translation of stem cell research: Points to consider in designing preclinical animal studies. Stem Cells Transl. Med. 2012, 1, 353–358
7. Lund, R.J.; Närvä, E.; Lahesmaa, R. Genetic and epigenetic stability of human pluripotent stem cells. Nat. Rev. Genet. 2012, 13, 732–744
8. OECD. Guidelines for the Testing of Chemicals. Available online: http://www.oecd.org/chemicalsafety/testing/oecdguidelinesforthetestingofchemicals.htm (accessed on 17 December 2014).
9. Kanemura, H.; Go, M.J.; Shikamura, M.; Nishishita, N.; Sakai, N.; Kamao, H.; Mandai, M.; Morinaga, C.; Takahashi, M.; Kawamata, S. Tumorigenicity studies of induced pluripotent stem cell (iPSC)-derived retinal pigment epithelium (RPE) for the treatment of age-related macular degeneration. PLoS One 2014, 9, e85336
10. Sykova, E.; Forostyak, S. Stem cells in regenerative medicine. Laser Ther. 2013, 22, 87–92
11. World Health Organization. Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks. Proposed Replacement of TRS 878, Annex 1. Available online: http://www.who.int/biologicals/Cell_Substrates_clean_version_18_April.pdf (accessed on 17 December 2014).
12. World Health Organization. Requirements for the Use of Animal Cells as in Vitro Substrates for the Production of Biologicals; WHO Technical Report Series No. 878, Annex 1. Available online: http://whglibdoc.who.int/trs/WHO_TRS_878.pdf (accessed on 17 December 2014).
13. Bailey, A.M. Balancing tissue and tumor formation in regenerative medicine. Sci. Transl. Med. 2012, 4, doi:10.1126/scitranslmed.3003685
14. Suzuki, S.; Iwamoto, M.; Saito, Y.; Fuchimoto, D.; Sembon, S.; Suzuki, M.; Mikawa, S.; Hashimoto, M.; Aoki, Y.; Najima, Y., et al. Il2rg gene-targeted severe combined immunodeficiency pigs. Cell Stem Cell 2012, 10, 753–758
15. Machida, K.; Suemizu, H.; Kawai, K.; Ishikawa, T.; Sawada, R.; Ohnishi, Y.; Tsuchiya, T. Higher susceptibility of NOG mice to xenotransplanted tumors. J. Toxicol. Sci.2009, 34, 123–127
16. Prochazka, M.; Gaskins, H.R.; Shultz, L.D.; Leiter, E.H. The nonobese diabetic scid mouse: Model for spontaneous thymomagenesis associated with immunodeficiency. Proc. Natl. Acad. Sci. USA 1992, 89, 3290–3294
17. Ciulla, T.A.; Criswell, M.H.; Danis, R.P.; Hill, T.E. Intravitreal Triamcinolone Acetonide Inhibits Choroidal Neovascularization in a Laser-Treated Rat Model. Arch. Ophthalmol.2001, 119, 399–404
18. Ciulla, T.A.; Criswell, M.H.; Danis, R.P.; Fronheiser, M.; Yuan, P.; Cox, T.A.; Csaky, K.G.; Robinson, M.R. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br. J. Ophthalmol. 2003, 87, 1032–1037
19. Kanemura, H.; Go, M.J.; Nishishita, N.; Sakai, N.; Kamao, H.; Sato, Y.; Takahashi, M.; Kawamata, S. Pigment Epithelium-Derived Factor Secreted from Retinal Pigment Epithelium Facilitates Apoptotic Cell Death of iPSC. Sci. Rep. 2013, 3 doi:10.1038/srep02334
20. Kuroda, T.; Yasuda, S.; Kusakawa, S.; Hirata, N.; Kanda, Y.; Suzuki, K.; Takahashi, M.; Nishikawa, S.; Kawamata, S.; Sato, Y. Highly sensitive in vitro methods for detection of residual undifferentiated cells in retinal pigment epithelial cells derived from human iPS cells. PLoS One 2012, 7, e37342.